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The aim of this study was to validate a molecular classification of colorectal cancer (CRC)
based on microsatellite instability (MSI), CpG island methylator phenotype (CIMP) status,
BRAF, and KRAS and investigate each subtype’s response to chemotherapy.
Design
This retrospective observational study included a population-based cohort of 878 CRC
patients. We classified tumours into five different subtypes based on BRAF and KRAS
mutation, CIMP status, and MSI. Patients with advanced stage II (T4N0M0) and stage III
tumours received 5-fluoruracil (5-FU)-based chemotherapy or no adjuvant treatment based
on clinical criteria. The main outcome was disease-free survival (DFS).
Results
Patients with the combination of microsatellite stable (MSS) tumours, BRAF mutation and
CIMP positive exhibited the worst prognosis in univariate (log rank P<0.0001) and multivariate
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analyses (hazard ratio 1.75, 95% CI 1.05–2.93, P = 0.03) after adjusting for age, sex, chemo-
therapy, and TNM stage. Treatment with 5-FU-based regimens improved prognosis in
patients with the combination of MSS tumours, KRAS mutation and CIMP negative (log rank
P = 0.003) as well as in patients with MSS tumours plus BRAF and KRAS wild-type and CIMP
negative (log-rank P<0.001). After adjusting for age, sex, and TNM stage in the multivariate
analysis, only patients with the latter molecular combination had independently improved
prognosis after adjuvant chemotherapy (hazard ratio 2.06, 95% CI 1.24–3.44, P = 0.005).
Conclusion
We confirmed the prognostic value of stratifying CRC according to molecular subtypes
using MSI, CIMP status, and somatic KRAS and BRAF mutation. Patients with traditional
chromosomally unstable tumours obtained the best benefit from adjuvant 5-FU-based
chemotherapy.
Introduction
Colorectal cancer (CRC) is one of the most prevalent neoplasms and an important cause of
death in Western countries [1]. In the last few years, several therapeutic options have improved
the survival of CRC patients, due in part to better comprehension of its molecular biology.
CRC has largely been considered a heterogeneous disease, with an increasing number of path-
ways involved in different subtypes. Therefore, it is plausible that these different subtypes
exhibit different behaviour in terms of not only overall prognosis, but also the response to
adjuvant chemotherapy. Recently, studies demonstrating the role of immunotherapy in MSI
tumours highlighted the importance of adequately classifying CRC patients in order to effec-
tively provide the best molecular-based treatment [2].
Phipps et al [3] and Sinicrope et al [4] proposed two molecular classifications with prognos-
tic implications based on different combinations of microsatellite instability (MSI), CpG island
methylator phenotype (CIMP) status, and BRAF and KRAS somatic mutations in tumours.
Thus, we can classify CRC into five subtypes according to the described pathways of colorectal
carcinogenesis [5] Studies have shown clinical and pathological differences between the sub-
types, as well as relevant differences in prognosis [3–7]. On the other hand, Guinney and col-
leagues proposed a new molecular classification based on gene expression profiling,[8;9] but
some difficulties have arisen in transferring this classification to clinical practice [10–12]. As
the molecular classification based on MSI, CIMP, BRAF, and KRAS [3] is simple and easy to
apply, the aim of our study was to reproduce and validate this classification and investigate the
response of each of subtypes to chemotherapy.
Material and methods
Study population
We enrolled a population-based cohort of 878 patients with CRC, available tumour tissue
and complete genotyping for BRAF,KRAS, CIMP and MSI status, from the nationwide and
multicentre EPICOLON I and EPICOLON II projects [13;14] in a retrospective observa-
tional study (Fig 1). Patients were included between years 2000–2001 in EPICOLON I and
2006–2007 in EPICOLON II. Adjuvant chemotherapy was administered following standard
clinical criteria, regardless the MMR status of the tumours. Oncologists that decided
Colorectal cancer molecular classification: Prognostic implications and response to chemotherapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0203051 September 6, 2018 2 / 13
Eva Herna´ndez-Illa´n received a grant from Instituto
de Salud Carlos III (FI12/00233). Mar Giner-
Calabuig received a grant from VALi+d. EXP ACIF/
2016/002. Miren Alustiza received a predoctoral
grant from ISABIAL (UGP-16-138). Other financial
support was obtained from Asociacio´n Española de
Gastroenterologı´a grants (Gonzalo Miño 2014,
Tamarite 2015, Grupo de endoscopia 2016).
Competing interests: The authors have declared
that no competing interests exist.
treatment with adjuvant chemotherapy were blinded to the MMR status of the tumours.
The institutional review board (IRB) of the Hospital General Universitario de Alicante
approved the study as well as IRBs of all the participant hospitals. All patients provided writ-
ten informed consent.
CRC samples
After the surgery of each CRC, tumor samples were obtained and paraffin-embedded at the
different participant hospitals. These paraffin-embedded samples were sent to the Hospital
General Universitario of Alicante. There, DNA was extracted from paraffin-embedded tissue
with the QIAamp DNA Investigator kit (QIAGEN, Hilden, Germany) and with the E.Z.N.A
Forensic DNA kit (OMEGA Biotek, Norcross, GA), according to manufacturer’s protocols.
Variables
We analysed patient age, sex, tumour location, date and stage at the time of CRC diagnosis,
BRAF and KRASmutation status, CIMP, and MSI status, treatment (surgical, chemotherapy,
radiotherapy, or biologic), and disease-free survival (DFS) time in months. We analysed the
response to adjuvant chemotherapy in patients with advanced stage II (TNM stage II and T4)
and stage III tumours. The main outcome was DFS. The follow-up of patients after surgery
was performed according to clinical practice guidelines with scheduled CEA measurements,
computed tomography and colonoscopy procedures [15;16].
Mutations in the BRAF and KRAS genes
The V600E BRAFmutation was detected by real-time PCR (ABI PRISM 7500, Applied Biosys-
tems, Foster City, CA) using specific TaqMan probes and allelic discrimination software as
Fig 1. Flow diagram of patients included in the study.
https://doi.org/10.1371/journal.pone.0203051.g001
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described previously [17]. The reporter fluorophore on the probes was 6-carboxyfluorescein
(FAM) for the mutant allele and VIC for the wild-type allele. We used the allelic discrimina-
tion software on the ABI Prism 7500 instrument to analyse the fluorescence data. KRASmuta-
tion at exon 1, including codons 12 and 13, was identified by DNA direct sequencing. We
assessed both mutations by direct amplicon sequencing with BigDye v1.1 terminators and a
3500 Genetic Analyzer (Applied Biosystems) [18].
CIMP analysis
Genomic DNA was modified with sodium-bisulphite using the EZ Methylation Gold Kit
(Zymo Research, Orange, CA). The PCR reaction contained bisulphite modified DNA, Hot-
Star Taq polymerase, forward primers, biotinylated reverse primers, and water. We analysed
markers by real-time methylight technology, considering a tumour CIMP-H when three of the
five analysed markers (CACNAG1, SOCS1,RUNX3, NEUROG1and MLH1) harboured aber-
rant hypermethylation. Each marker was classified as methylated when the mean percentage
was greater than 5% for CACNAG1, SOCS1,RUNX3, and MLH1, and 10% for NEUROG1.
MSI analysis
We tested for MSI using either the 5-marker panel proposed by the National Cancer Institute
or a pentaplex of mononucleotide repeats (BAT25, BAT26, NR21, NR24, and NR27), classify-
ing tumours as microsatellite stable (MSS) or unstable (MSI). The presence of two or more
unstable markers defined a tumour as MSI [19;20].
Chemotherapy regimen
The adjuvant chemotherapy regimen followed standard clinical criteria. Patients with advanced
stage II and stage III tumours received 5-fluoruracil (5-FU) based chemotherapy (5-FU, capeci-
tabine, 5-FU plus oxaliplatin (FOLFOX), or 5-FU plus irinotecan (FOLFIRI)) as first line treat-
ment following standard schedules and doses according to the local decision of the responsible
oncologist. Oncologists were blinded to the BRAF,KRAS, MSI or CIMP tumour status. The
decision to give or not to give chemotherapy drugs was based on the oncologist criteria in each
of the participating centres.
Classification of CRC
We classified tumours into five subtypes according to the model proposed by Phipps et al [3]
and shown in Table 1. Subtype 1, sporadic serrated and unstable tumours; subtype 2, sporadic
serrated tumours without MSI; subtype 3, traditional tumours with KRASmutations or ser-
rated tumours from the alternative serrated pathway; subtype 4, traditional chromosomally
unstable (CIN) tumours without KRASmutations; and subtype 5, familial unstable tumours.
Table 1. Molecular classification of colorectal cancer. MSI, microsatellite instability; MSS, microsatellite stability.
MMR CIMP BRAF KRAS
Subtype 1 MSI + + -
Subtype 2 MSS + + -
Subtype 3 MSS - - +
Subtype 4 MSS - - -
Subtype 5 MSI - - -
https://doi.org/10.1371/journal.pone.0203051.t001
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Statistical analysis
In order to maximize the number of cases available for analysis, we performed a multiple impu-
tation model to complete cases with missing values at one (n = 141) or two molecular markers
(n = 16) [3;21]. We carried out 25 rounds of imputation using the automatic model of SPSS soft-
ware until an appropriate model was obtained [22]. We considered a deviation proportion with
respect to original data<0.1% as appropriate; it reliably reproduced the percentage of alter-
ations at the four markers in the complete cases model. The imputation took into account
BRAF and KRAS status, presence of CIMP, MMR status, sex, age, TNM stage, tumour location,
treatment with chemotherapy, and DFS time. After imputation, we classified cases into subtypes
1 to 5. Cases with no defined molecular combination were defined as the “unclassified” subtype.
We performed several simulation analyses before concluding the validation of the imputation
model, including relative risks (RRs) and hazard ratios (HRs). Original data, non-including
patients with missing values using the imputation model, are available as Supplementary mate-
rial and referred as complete-cases model (S1–S4 Tables).
Parametric continuous variables are reported as mean ± standard deviation (SD) and non-
parametric continuous variables as median (Q2-Q3 interquartile range). We compared cate-
gorical variables using chi-squared.
For overall prognosis, we compared differences in DFS time (interval of time between
remission of disease and their reappearance) among the five subtypes by log rank test in a uni-
variate analysis, expressing it graphically with Kaplan-Meier survival curves. The multivariate
analysis was performed by adjusting for potential confounder and interaction variables (age,
sex, TNM stage, and chemotherapy) in a Cox regression model. Subtype 4 was the subtype of
reference.
For the adjuvant chemotherapy response, we performed several univariate analyses for each
subtype. The multivariate analysis was adjusted for the different subtypes, age, sex and TNM
stage. As comparisons were made in each subgroup between patients receiving and not receiv-
ing adjuvant chemotherapy, we did not establish a reference group.
All P-values were two-sided, with P<0.05 considered significant. All data were analysed
using SPSS 22.0 software.
Results
Among the 878 patients, complete analysis of the four molecular markers was possible in 721
(Fig 1). A total of 141 cases had one missed marker, and 16 cases had two missed markers.
These cases were completed using the multiple imputation model. The median follow-up was
52 months (interquartile range 16–64). A total of 241 cases (27%) had a CIMP-high pattern. A
total of 324 cases had a somatic KRASmutation (37%) and 54 had somatic mutations in BRAF
(6%). Eighty cases (10%) had MSI. According to the proposed model, we could classify 677
patients (77%) into subtypes 1 to 5: 25 (3%) subtype 1, 22 (3%) subtype 2, 218 (25%) subtype 3,
388 (44%) subtype 4, and 24 (3%) subtype 5. The remaining cases (n = 201, 23%) were tumours
of the “unclassified” molecular subtype (Table 2). The median age was lower in cases with sub-
type 5 tumours compared to the other subtype groups, which had similar median ages. Sex
was homogenously distributed, except in the subtype 5 group, which had a predominance of
women. The majority of tumours were TNM stages II or III at diagnosis, with no significant
differences among the subtypes. A majority of subtype 1 tumours were right-sided, whereas
subtypes 3 and 4 were preferably located in the left colon. The proportion of patients treated
with chemotherapy differed slightly among subtypes (Table 2).
Regarding the “unclassified” subtype”, there were observed three major genetic combina-
tions among the 201 cases. Of them, 93 (46.3%) had CIMP-H and KRAS-mutation, which were
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equally distributed regarding sex, age and tumor location. Other 68 cases (33.8%) had CIMP-H
in combination with any other genetic alteration. These were preferentially men (63%) and
located in left colon (71%). Finally, 21 showed CIMP-H and MSI combination with BRAF wild-
type (10.4%). Characteristics of the “unclassified” subtype are shown in the S1 Table.
Overall prognosis
Fig 2 shows the Kaplan Meier survival curves for the different CRC subtypes. In the univariate
analysis, subtype 2 had the lowest DFS, below 30%. In contrast, subtype 5 had a DFS rate at the
end of the follow-up period of up to 80% (log rank P<0.001, Table 3).
Multivariate analysis showed that age (P<0.001), TNM stage (P<0.001), and chemotherapy
(P<0.001) were significantly influential in regards to DFS. Regarding the different subtypes,
only patients with subtype 2 (HR = 1.75, P = 0.03) had a different prognosis with respect to the
subtype of reference after adjusting for age, sex, chemotherapy, and TNM (Table 3). Subtype 3
also revealed a trend for different prognosis (HR = 1.2, P = 0.109). Trends were similar in the
complete-cases model, although no significantly independent better prognosis was found in
subtype 2 (S2 Table).
Prognosis after adjuvant chemotherapy
We analysed the response to chemotherapy in 324 patients with advanced stage II (T4N0M0)
or stage III CRC (Table 4).
In this group, a total of 114 patients did not receive adjuvant chemotherapy. Overall, che-
motherapy improved DFS time (log rank P<0.001) in the univariate analysis. Regarding CRC
subtypes, there was a clear benefit from chemotherapy in subtypes 3 and 4. In both subtypes,
Table 2. Clinical characteristics of patients according to subtype in multiple imputation model. St, subtype. DFS, disease-free survival.
St 1 (n = 25
[2.8%])
St 2 (n = 22
[2.5%])
St 3 (n = 218
[24.8%])
St 4 (n = 388
[44.2%])
St 5 (n = 24
[2.7%])
Unclassified (n = 201
[22.9%])
Median of age (years) 77 74 73 72 66 73
Age at diagnosis
(years, %)
<40 0 (0) 0 (0) 2 (0.9) 2 (0.5) 0 (0) 2 (1.0)
40–49 0 (0) 1 (4.5) 14 (6.4) 11 (2.8) 3 (12.5) 4 (2.0)
50–59 2 (8.0) 2 (9.1) 17 (7.8) 41 (10.6) 5 (20.8) 17 (8.5)
60–69 9 (36.0) 4 (18.2) 39 (17.9) 99 (25.5) 6 (25.0) 43 (19.7)
>70 14 (56.0) 15 (68.2) 146 (67.0) 235 (60.6) 10 (41.7) 136 (67.2)
Sex, n (%) Male 12 (48.0) 10 (50.0) 134 (61.5) 245 (63.1) 8 (33.3) 111 (55.2)
Female 13 (52.0) 10 (50.0) 84 (38.5) 143 (36.9) 16 (66.7) 90 (44.8)
TNM stage at
diagnosis
I 3 (12.0) 1 (4.5) 45 (20.6) 53 (13.7) 6 (25.0) 30 (14.9)
II 14 (56.0) 3 (13.6) 68 (31.2) 157 (40.5) 13 (54.2) 71 (35.3)
III 7 (28.0) 10 (45.5) 67 (30.7) 124 (32.0) 2 (8.3) 70 (34.8)
IV 1 (4.0) 8 (36.4) 38 (17.4) 54 (13.9) 3 (12.5) 30 (14.9)
Tumor location, n (%) Right colon 23 (92.0) 13 (59.1) 69 (31.7) 66 (17.0) 14 (58.3) 91 (45.3)
Left colon 2 (8.0) 9 (40.9) 149 (68.3) 322 (83.0) 10 (41.7) 110 (54.7)
1st line Chemotherapy 5-FU or
Capecitabine
5 (20.0) 9 (40.9) 53 (24.3) 116 (29.9) 9 (37.5) 39 (19.4)
FOLFOX 3 (12.0) 3 (13.6) 34 (15.6) 88 (22.7) 2 (8.3) 45 (22.4)
No CT 17 (68.0) 10 (45.5) 131 (60.1) 184 (47.4) 13 (54.2) 117 (58.2)
DFST, months
(median)
60.0 18.0 38.7 50.9 62.8 54.8
https://doi.org/10.1371/journal.pone.0203051.t002
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the patients had higher DFS rates when they received chemotherapy (log rank P = 0.003 for
subtype 3 and P<0.001 for subtype 4, Fig 3A and 3B and Table 5).
A multivariate analysis was also performed for the different subtypes (Table 5). After
adjusting for age, sex, and TNM stage, only patients with subtype 4 CRC independently exhib-
ited significant benefit with chemotherapy (subtype 3: HR = 1.93, 95% CI 0.86–4.34, P = 0.1;
subtype 4: HR = 2.06, 95% CI 1.24–3.44, P = 0.005). These results were similar in the com-
plete-cases model (S3 and S4 Tables).
Fig 2. Kaplan-Meier survival curves comparing disease-free survival in colorectal cancer patients by tumour subtype.
https://doi.org/10.1371/journal.pone.0203051.g002
Table 3. Overall prognosis for different subtypes in the multiple imputation model. Subtype 4 serves as a reference. The analysis was adjusted for sex, age, chemother-
apy, and TNM as potential confounder factors. CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval.
Case participants Relapse or CRC-death
Number % Number % HR 95% CI P value
Subtype 1 25 2.8 8 32.0 0.59 0.29–1.20 0.144
Subtype 2 22 2.5 16 76.2 1.75 1.05–2.93 0.032
Subtype 3 218 24.8 117 54.9 1.21 0.96–1.52 0.109
Subtype 4 388 44.2 191 50.3 1.0 Ref —
Subtype 5 24 2.7 7 29.2 0.56 0.26–1.19 0.131
Unclassified 201 22.9 85 42.9 0.84 0.65–1.09 0.187
https://doi.org/10.1371/journal.pone.0203051.t003
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Discussion
Our results confirm that, as suggested in previous studies [3;4], classification of the molecular
profile of CRC using BRAF,KRAS, MSI, and CIMP status can identify differences in prognosis.
Our results confirm the poorest prognosis found for subtype 2 in previous cohorts, unaffected
by age or TNM stage. This lower survival rate for subtype 2 tumours suggests that the combi-
nation of CIMP and BRAFmutation confers a poor prognosis in stable tumours, whereas the
same combination in tumours with MSI (i.e., subtype 1) evolves in a completely different way.
Moreover, our results show that the more common subtypes 3 and 4 benefit from adjuvant
5-FU-based chemotherapy, but only in subtype 4 CRC patients is this benefit independent of
Table 4. Clinical characteristics of patients with advanced stage II and stage III tumours in multiple imputation model. DFST, disease-free survival time. St, Subtype.
St 1
(n = 9 [2.8%])
St 2
(n = 10 [3.1%])
St 3





(n = 6 [1.9%])
Unclassified (n = 80
[24.7%])
Median of age (years) 74 74 72 72 72 73
Age at diagnosis (years,
%)
<40 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.3)
40–49 0 (0) 0 (0) 4 (5.2) 3 (2.1) 1 (16.7) 1 (1.3)
50–59 0 (0) 1 (10.0) 8 (10.4) 15 (10.6) 0 (0) 4 (5.0)
60–69 4 (44.4) 2 (20.0) 16 (20.8) 32 (22.5) 2 (33.3) 18 (22.5)
>70 5 (55.6) 7 (70.0) 49 (65.6) 92 (64.8) 3 (50.0) 56 (70.0)
Sex, n (%) Male 4 (44.4) 4 (40.0) 40 (51.9) 85 (59.9) 2 (33.3) 36 (45.0)
Female 5 (55.6) 6 (60.0) 37 (48.1) 57 (40.1) 4 (66.7) 44 (55.0)
TNM stage at diagnosis II 2 (22.2) 0 (0) 10 (13.0) 18 (12.7) 4 (66.7) 10 (12.5)
III 7 (77.8) 10 (100) 67 (87.0) 124 (87.3) 2 (33.3) 70 (87.5)
Tumor location, n (%) Right colon 7 (77.8) 6 (60.0) 24 (31.2) 25 (17.6) 4 (66.7) 35 (43.8)
Left colon 2 (22.2) 4 (40.0) 53 (68.8) 117 (82.4) 2 (33.3) 45 (56.2)
1st line Chemotherapy 5-FU or
Capecitabine
3 (33.3) 4 (40.0) 25 (32.5) 50 (35.2) 3 (50.0) 22 (27.5)
FOLFOX 1 (11.1) 2 (20.0) 22 (28.6) 49 (34.5) 0 (0) 29 (36.3)
No CT 5 (55.5) 4 (40.0) 30 (39.0) 43 (30.3) 3 (50.0) 29 (36.3)
DFST, months (median) 57.1 32.5 30.9 46.7 47.8 55.7
https://doi.org/10.1371/journal.pone.0203051.t004
Fig 3. Disease-free survival in patients with advanced stage II and stage III colorectal cancer according to whether they received adjuvant chemotherapy. A) subtype
3 patients and B) subtype 4 patients.
https://doi.org/10.1371/journal.pone.0203051.g003
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sex, age, and TNM stage. The response in other subtypes cannot be evaluated due to their
small representation in our cohort.
Subtypes 1 and 2 belong to the serrated pathway of carcinogenesis, with serrated polyps as
the precursor lesion, whereas subtypes 4 and 5 follow the traditional adenoma-carcinoma
pathway with MSS (subtype 4) tumours or MSI (subtype 5). On the other hand, subtype 3
includes tumours that can originate in serrated or adenomatous polyps, with the KRAS
somatic mutation as their molecular hallmark [5]. Different studies have shown discordant
results with respect to the prognostic value of some molecular markers [23;24]. BRAFV600E
has traditionally been linked to a poor prognosis, with many authors proposing it as an inde-
pendent predictor of low survival [25]. However, other studies have found differences accord-
ing to MMR status, showing better survival rates in tumours with MSI than in MSS tumours.
[26] Something similar has been seen with CIMP [27]; though many studies have not attrib-
uted any prognostic value [23], others proposed it is a predictor of short survival, and even of
high survival if MSI appeared concomitantly [28]. Taken together, all these discordances could
be due to the consideration of isolated markers instead of combinations of them [10]. Group-
ing according to the proposed molecular pathways led to different and well defined survival
curves. Recently, Guinney et al [8] proposed a new molecular classification of CRC based on
gene expression datasets. This classification divides CRC into four subtypes: MSI immune
with MSI, BRAFmutated, and CIMP positive tumours; canonical with WNT and MYC activa-
tion; metabolic with KRASmutated tumours; and mesenchymal, characterized by stromal
infiltration and TGF-β activation. The majority of the proposed molecular subtypes somehow
coincide with those in our study [10]. However, some patients are very difficult to classify,
especially those from the mesenchymal subtype, which lacks convenient molecular makers.
Although this classification can be considered the most robust classification system currently
available for CRC, with a clear biological basis and comprehensive tumour characterization
based on advances in genomic technology, the challenges in data interpretation and clinical
application have not yet been adequately overcome [10].
In our knowledge, this is the first study that examines the classification of CRC proposed by
Phipps and tries to correlate the response of each subtype to chemotherapy and compare
among them. Previous studies using these classifications did not analyse the role of chemother-
apy in the evolution of CRC patients in regards to molecular subtypes. Unfortunately, our
Table 5. Chemotherapy response of different subtypes in univariate and multivariate analyses using the multiple imputation model. The multivariate analysis was
adjusted for sex, age, and TNM stage for each subtype. CT, chemotherapy; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval.
Univariate analysis Multivariate analysis
CT Number of patients Median of DFS time (months) P value HR 95% CI P value
Subtype 1 Yes 4 39.3 0.620 0.53 0.19–1.46 0.220
No 5 62.2
Subtype 2 Yes 6 44.6 0.068 0.40 0.04–3.92 0.430
No 4 9.6
Subtype 3 Yes 47 49.5 0.003 1.93 0.86–4.34 0.111
No 30 27.8
Subtype 4 Yes 99 54.2 0.000 2.06 1.24–3.44 0.005
No 43 29.0
Subtype 5 Yes 3 63.9 0.107 1.01 0.31–3.28 0.991
No 3 16.9
Unclassified Yes 51 58.6 0.015 1.71 0.74–3.96 0.208
No 29 39.0
https://doi.org/10.1371/journal.pone.0203051.t005
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study does not have enough power to confirm this lack of response of MSI subtypes 1 and 5
due to the small sample size. However, this lack of response to 5-FU-based chemotherapy by
tumours with MSI was well established in previous studies [29–32]. Our results highlight that
the more common CRC subtypes seem to improve with chemotherapy in the univariate analy-
sis (subtypes 3 and 4). These benefits were only maintained in subtype 4 in the multivariate
analysis, revealing an advantage of this subtype in 5-FU-based chemotherapy, and a potential
limited effect of this treatment in subtype 3 CRC patients. On the other hand, we also observed
a trend of obtaining a benefit from chemotherapy for subtype 2. The hypothesis that patients
with molecularly different tumours have different responses to chemotherapy is clearly plausi-
ble given the biological diversity found between CRC tumours. It is especially interesting to
investigate the response of subtype 2 and 3 CRC, as they are biologically different from the
classical CIN CRC. Another point that requires specific research is the possible role of new tar-
geted molecules in the different molecular CRC subtypes. Improved survival using immuno-
therapy in CRC with MSI was demonstrated recently [2], and there is a biological explanation
for both: the lack of effect of conventional 5-FU-based chemotherapy and the benefit from
immunotherapy in this subtype of CRC. The role of immunotherapy or other types of chemo-
therapy could be more appropriately investigated if we were able to adequately classify CRC in
different subtypes. Larger cohorts are needed for differentially investigating the role of differ-
ent drugs in the diverse molecular landscape of CRC.
This study has some limitations that should be considered. First, it is important to note that
we could appropriately classify only 71% of these cases using the molecular markers. There are
at least two reasons for this. First, biology is not perfect and may include aberrant combina-
tions with an unpredictable course. Second, it is possible that there are other molecular path-
ways of colorectal carcinogenesis not included in this classification and molecular subtypes of
CRC with prognostic implications could include more than those proposed. Another limita-
tion of our study is the small number of patients receiving adjuvant chemotherapy in minority
subtypes (i.e., 1, 2, and 5), precluding the possibility of appropriately determining the response
to 5-FU-based chemotherapy in these subtypes. In addition, our study shows a higher propor-
tion of CIMP positive tumors (27%) than other studies [3]. This could be likely attributable to
the characteristics of our sample, such as the mean age of our unselected consecutive popula-
tion, with more than 60% older than 70 years-old. Finally, the decision regarding giving che-
motherapy in stage II and III patients was based on clinical criteria. Previous studies of these
CRC subtypes were nested in randomized clinical trials comparing different chemotherapy
regimens [3,4], which precludes obtaining information about the predictive value of this sub-
type classification. We can investigate the role of adjuvant 5-FU-based chemotherapy only if
there is a group of patients that do not receive treatment, and that could be considered a
strength of our study. However, basing the treatment decision on clinical criteria can provoke
some biases, because it is possible that this clinical decision was based on factors such as age
and performance status, avoiding chemotherapy in people in the worst health status. Neverthe-
less, that scenario otherwise allows us to study the effect of adjuvant chemotherapy in the dif-
ferent subtypes considering the difficulty obtaining other data and given that it could be
considered unethical to design a randomized clinical trial with an untreated control group in
advanced stage II and stage III CRC patients.
In summary, our results confirm the prognostic value of stratifying CRC according to
molecular subtypes using MSI and CIMP status and somatic KRAS and BRAFmutations. The
use of this classification can be helpful when making clinical decisions in the management of
CRC patients. Serrated CRC with CIMP and somatic BRAFmutation has the worst prognosis.
5-FU-based chemotherapy provides a benefit in subtypes 3 and 4 in regards to DFS time, but
this benefit was independent after adjusting for sex, age, and TNM stage only in subtype 4
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tumours representing the traditional CIN pathway. A better understanding of the biology of
CRC, description of new pathways of colorectal carcinogenesis, and determination of driver
mutations will improve and complete this classification in the near future. Research should
focus on molecularly targeted therapy for the different subtypes, especially for those with the
worst prognosis.
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